Translating microbiome and infection-biology research into precision diagnostic technologies
I am contributing to the scientific and translational development of Resistobiome Private Limited, a biotechnology venture established in July 2026 to advance biomarker-driven solutions in antimicrobial resistance, microbiome science and infection-associated disease.
Corporate Identity Number: U21009MP2026PTC085343; Location: Indore, Madhya Pradesh, India
Selected under the Healthier India Program-Pre-Incubation Track for milestone-driven development of a non-invasive, plasma-and-saliva-based screening platform for early post-viral cardiometabolic, thrombotic, endothelial and thyroid-axis risk stratification.
The programme provides validation support, prototype and regulatory guidance, commercialization mentoring, access to the FITT incubation ecosystem and approved grant support of up to ₹5 lakh.